Our engineered cell model allows tightly controlled CRTC1-MAML2 shRNA expression and, thus, will be useful for modeling pathways and networks, as well as probing the mechanisms of action and tumor phenotypes during MEC progression. The gene discussed is MAML2; the disease is neoplasm.